LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $101 | -16.5% | 85,336 | 0.0% | 0.00% | – |
| Q2 2023 | $121 | -9.7% | 85,336 | -4.2% | 0.00% | – |
| Q1 2023 | $134 | +28.8% | 89,100 | 0.0% | 0.00% | – |
| Q4 2022 | $104 | -99.9% | 89,100 | 0.0% | 0.00% | – |
| Q3 2022 | $101,000 | -11.4% | 89,100 | +23.1% | 0.00% | – |
| Q2 2022 | $114,000 | +21.3% | 72,400 | +18.5% | 0.00% | – |
| Q1 2022 | $94,000 | -34.3% | 61,091 | +4.6% | 0.00% | – |
| Q4 2021 | $143,000 | -51.0% | 58,391 | -49.5% | 0.00% | – |
| Q3 2021 | $292,000 | +90.8% | 115,691 | +115.3% | 0.00% | – |
| Q2 2021 | $153,000 | +48.5% | 53,731 | +22.7% | 0.00% | – |
| Q1 2021 | $103,000 | – | 43,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $41,223,872 | 3.66% |
| Raffles Associates | 1,587,739 | $1,873,532 | 2.48% |
| Defender Capital, LLC. | 5,184,510 | $6,117,722 | 2.22% |
| Prescott General Partners LLC | 1,851,851 | $2,185,184 | 0.14% |
| DCF Advisers, LLC | 82,751 | $97,646 | 0.05% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $63,450 | 0.05% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $922,484 | 0.02% |
| Fort Sheridan Advisors LLC | 83,931 | $99,039 | 0.02% |
| MAI Capital Management | 954,688 | $1,126,532 | 0.02% |
| Piscataqua Savings Bank | 12,499 | $14,623 | 0.01% |